FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2562266793> ?p ?o ?g. }

• W2562266793 abstract "Abstract Disease relapse is the most common cause of treatment failure after allo-SCT for high risk AML and MDS. Treatment options for patients with recurrent disease are extremely limited and re-induction chemotherapy, when administered, is often either poorly tolerated or ineffective. Azacitidine (AZA) is a DNMT inhibitor which is well tolerated and clinically active in high risk AML/MDS. Of interest AZA also up-regulates the expression of tumor antigens and plausibly augments a graft-versus-leukemia effect. A number of small studies have suggested clinical activity of AZA in patients who relapse after an allograft for AML/MDS but both overall response rate and predictors of response remain unknown. We report the first systematic study of the activity and tolerability of AZA in patients who relapsed after allo-SCT for AML/MDS. 204 patients who relapsed at a median of 6.5 months (range, 1-49) after an allograft for AML (n=130) or MDS (n=74) were studied. The median age was 58 years (range 22-76). 89 patients were transplanted using a matched sibling donor and 115 from an adult unrelated donor. 47 patients received a myeloablative and 157 a reduced intensity conditioning regimen. AZA was administered for 5-7 consecutive days every month. The median duration of AZA treatment was 68 days (inter-quartile range 24-154 days). 66 patients received additional donor lymphocyte infusions (DLI) at a median of 43 days after commencement of AZA. AZA was well tolerated in the majority of patients. 57 patients developed Grade 3-4 non-hematological toxicities 47 of which were infectious complications and likely also attributable to relapsed disease. 4 patients developed Grade 3-4 acute GVHD after AZA treatment. 45 (22%) patients achieved a complete remission (CR) or partial remission after AZA administration at a median of 114 days after commencement of treatment. 31 (15%) patients achieved a CR. The median number of courses of AZA to achieve a clinical response was three. In multivariable analysis the only significant factor determining improved response to AZA was relapse occurring more than 12 months post-transplant. The median overall survival (OS) for all patients was 6 months after the commencement of AZA therapy. In patients who achieved a CR the 2 year OS after commencement of AZA was 38.5% versus 11% for the whole population (p= 0.001). In multivariable analysis OS was determined by the occurrence of disease relapse more than 6 months post-transplant and achievement of a CR after AZA therapy. Of note, there was no significant difference in response rates to AZA between patients with relapsed AML or MDS. Concurrent administration of DLI did not improve either response or survival rates. In conclusion, these data confirm the ability of AZA to salvage a proportion of patients with AML or MDS who relapse after an allogeneic SCT and identify prognostic factors of response. The response and survival rates achieved with salvage AZA are comparable to those previously reported with either intensive chemotherapy or DLI. We conclude AZA represents an important and relatively well-tolerated new treatment option in the management of selected patients with AML and MDS who relapse after allo-SCT. Disclosures Craddock: Celgene: Grants Other, Honoraria. Kroger:Celgene: Research Funding. Mohty:Celgene: Research Funding." @default.
• W2562266793 created "2017-01-06" @default.
• W2562266793 creator A5001646221 @default.
• W2562266793 creator A5005481013 @default.
• W2562266793 creator A5008084507 @default.
• W2562266793 creator A5010183839 @default.
• W2562266793 creator A5022161221 @default.
• W2562266793 creator A5028365885 @default.
• W2562266793 creator A5034093405 @default.
• W2562266793 creator A5036207495 @default.
• W2562266793 creator A5040417184 @default.
• W2562266793 creator A5050987906 @default.
• W2562266793 creator A5058925624 @default.
• W2562266793 creator A5076077834 @default.
• W2562266793 creator A5076984999 @default.
• W2562266793 creator A5085146093 @default.
• W2562266793 creator A5090852676 @default.
• W2562266793 date "2014-12-06" @default.
• W2562266793 modified "2023-09-30" @default.
• W2562266793 title "Activity and Tolerability of Azacitidine in Patients Who Relapse after Allogeneic Stem Cell Transplantation (allo-SCT) for Acute Myeloid Leukemia (AML) and Myelodysplasia (MDS): a Survey from the European Society for Blood and Marrow Transplantation (EBMT" @default.
• W2562266793 doi "https://doi.org/10.1182/blood.v124.21.2506.2506" @default.
• W2562266793 hasPublicationYear "2014" @default.
• W2562266793 type Work @default.
• W2562266793 sameAs 2562266793 @default.
• W2562266793 citedByCount "1" @default.
• W2562266793 countsByYear W25622667932015 @default.
• W2562266793 crossrefType "journal-article" @default.
• W2562266793 hasAuthorship W2562266793A5001646221 @default.
• W2562266793 hasAuthorship W2562266793A5005481013 @default.
• W2562266793 hasAuthorship W2562266793A5008084507 @default.
• W2562266793 hasAuthorship W2562266793A5010183839 @default.
• W2562266793 hasAuthorship W2562266793A5022161221 @default.
• W2562266793 hasAuthorship W2562266793A5028365885 @default.
• W2562266793 hasAuthorship W2562266793A5034093405 @default.
• W2562266793 hasAuthorship W2562266793A5036207495 @default.
• W2562266793 hasAuthorship W2562266793A5040417184 @default.
• W2562266793 hasAuthorship W2562266793A5050987906 @default.
• W2562266793 hasAuthorship W2562266793A5058925624 @default.
• W2562266793 hasAuthorship W2562266793A5076077834 @default.
• W2562266793 hasAuthorship W2562266793A5076984999 @default.
• W2562266793 hasAuthorship W2562266793A5085146093 @default.
• W2562266793 hasAuthorship W2562266793A5090852676 @default.
• W2562266793 hasConcept C104317684 @default.
• W2562266793 hasConcept C126322002 @default.
• W2562266793 hasConcept C143998085 @default.
• W2562266793 hasConcept C150194340 @default.
• W2562266793 hasConcept C185592680 @default.
• W2562266793 hasConcept C190727270 @default.
• W2562266793 hasConcept C197934379 @default.
• W2562266793 hasConcept C2776239401 @default.
• W2562266793 hasConcept C2777408962 @default.
• W2562266793 hasConcept C2778375690 @default.
• W2562266793 hasConcept C2778729363 @default.
• W2562266793 hasConcept C2779695342 @default.
• W2562266793 hasConcept C2780007613 @default.
• W2562266793 hasConcept C2780817109 @default.
• W2562266793 hasConcept C2781413609 @default.
• W2562266793 hasConcept C2911091166 @default.
• W2562266793 hasConcept C55493867 @default.
• W2562266793 hasConcept C71924100 @default.
• W2562266793 hasConcept C90924648 @default.
• W2562266793 hasConceptScore W2562266793C104317684 @default.
• W2562266793 hasConceptScore W2562266793C126322002 @default.
• W2562266793 hasConceptScore W2562266793C143998085 @default.
• W2562266793 hasConceptScore W2562266793C150194340 @default.
• W2562266793 hasConceptScore W2562266793C185592680 @default.
• W2562266793 hasConceptScore W2562266793C190727270 @default.
• W2562266793 hasConceptScore W2562266793C197934379 @default.
• W2562266793 hasConceptScore W2562266793C2776239401 @default.
• W2562266793 hasConceptScore W2562266793C2777408962 @default.
• W2562266793 hasConceptScore W2562266793C2778375690 @default.
• W2562266793 hasConceptScore W2562266793C2778729363 @default.
• W2562266793 hasConceptScore W2562266793C2779695342 @default.
• W2562266793 hasConceptScore W2562266793C2780007613 @default.
• W2562266793 hasConceptScore W2562266793C2780817109 @default.
• W2562266793 hasConceptScore W2562266793C2781413609 @default.
• W2562266793 hasConceptScore W2562266793C2911091166 @default.
• W2562266793 hasConceptScore W2562266793C55493867 @default.
• W2562266793 hasConceptScore W2562266793C71924100 @default.
• W2562266793 hasConceptScore W2562266793C90924648 @default.
• W2562266793 hasLocation W25622667931 @default.
• W2562266793 hasOpenAccess W2562266793 @default.
• W2562266793 hasPrimaryLocation W25622667931 @default.
• W2562266793 hasRelatedWork W1605116582 @default.
• W2562266793 hasRelatedWork W2001421019 @default.
• W2562266793 hasRelatedWork W2040073738 @default.
• W2562266793 hasRelatedWork W2341077074 @default.
• W2562266793 hasRelatedWork W2568193238 @default.
• W2562266793 hasRelatedWork W2573880216 @default.
• W2562266793 hasRelatedWork W2581220283 @default.
• W2562266793 hasRelatedWork W2602570575 @default.
• W2562266793 hasRelatedWork W2770466614 @default.
• W2562266793 hasRelatedWork W2781565767 @default.
• W2562266793 hasRelatedWork W2906853702 @default.
• W2562266793 hasRelatedWork W2945232100 @default.
• W2562266793 hasRelatedWork W2979833693 @default.
• W2562266793 hasRelatedWork W2979933852 @default.
• W2562266793 hasRelatedWork W3001758319 @default.
• W2562266793 hasRelatedWork W3001987673 @default.
• W2562266793 hasRelatedWork W3048559248 @default.

• next